Tezepelumab demonstrated rapid and sustained clinical improvements in nasal polyp burden and symptom control, with effects ...

Longitudinal evaluation of SNOT-22 can distinguish patients with chronic rhinosinusitis with nasal polyps who respond quickly ...

Chronic rhinosinusitis with nasal polyps (CRSwNP) inflammatory endotypes are associated with long-term air pollutant and allergen exposure.

UK-based pharmaceutical company GSK has reported positive outcomes from two Phase III trials of depemokimab for treating ...

USA: In a recent exposure-matched study, researchers found that long-term exposure to fine particulate matter (PM2.5) may ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

Simultaneously, the three regulators are also reviewing a second potential indication for depemokimab as an add-on therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). GSK has said ...

Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

Several possible mechanisms have been proposed, including microbes (bacteria, fungi, viruses), biofilm formation, staphylococcal superantigen (most often associated with CRSwNP), osteitis and ...